Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Up 37.2% in December

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 25,800 shares, a growth of 37.2% from the December 15th total of 18,800 shares. Currently, 2.5% of the company’s shares are sold short. Based on an average trading volume of 40,700 shares, the days-to-cover ratio is presently 0.6 days.

Pasithea Therapeutics Trading Up 1.2 %

Pasithea Therapeutics stock opened at $2.48 on Friday. The business’s 50-day simple moving average is $2.89 and its 200 day simple moving average is $4.08. Pasithea Therapeutics has a 12-month low of $2.20 and a 12-month high of $9.25.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.